MPO’s Most-Read Stories This Week—Aug. 12

Products, personnel and procurement produced sizable pageviews this past week on MPO’s website.

Product news was dominated by the start of Magenta Medical Ltd.’s FDA-approved study of its Elevate percutaneous Left Ventricular Assist Device (pLVAD). The study began with the treatment of two patients: one in Mount Sinai Health System and one in St. Francis Hospital and Heart Center, both in New York, N.Y.

Other traffic-driving product news came from Quanta Dialysis Technologies, which earned FDA 510(k) clearance for an expanded indication of its compact hemodialysis device, and Abbott, which gained FDA clearance for its Alinity h-series hematology system, enabling U.S. labs to run complete blood counts (CBCs) as a part of its Alinity family of diagnostic tests.

Heraeus Medevio lured cybervisitors to the site with word of its new president, while Henry Schein caught readers’ attention through its deal to acquire a majority ownership in Shield Healthcare.

1. First Patients Treated in U.S. With World’s Smallest Heart Pump

2. Heraeus Medevio Appoints Heiko Specht as President

3. Quanta Earns FDA Nod for Expanded CRRT Indication

4. Henry Schein to Buy Majority Stake in Shield Healthcare

5. Abbott’s Alinity h-Series Lab Instruments OK’d for Complete Blood Counts